Mittie Doyle Sells 1,450 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the sale, the insider owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, April 6th, Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70.
• On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $18.16 on Friday. Avalo Therapeutics, Inc. has a one year low of $4.55 and a one year high of $24.27. The company has a 50-day simple moving average of $15.93 and a 200-day simple moving average of $16.11. The firm has a market capitalization of $954.78 million, a P/E ratio of -3.33 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, sell-side analysts forecast that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. UBS Group AG raised its holdings in Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after purchasing an additional 432,608 shares in the last quarter. Moody Aldrich Partners LLC bought a new position in Avalo Therapeutics during the 4th quarter valued at $2,419,000. Cantor Fitzgerald L. P. bought a new position in Avalo Therapeutics during the 3rd quarter valued at $1,083,000. Nan Fung Trinity HK Ltd. bought a new position in Avalo Therapeutics during the 4th quarter valued at $3,432,000. Finally, Boothbay Fund Management LLC increased its position in shares of Avalo Therapeutics by 1,916.6% during the 3rd quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock valued at $2,902,000 after purchasing an additional 216,976 shares during the period. 87.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on AVTX. Citizens Jmp reduced their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Mizuho increased their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Wedbush lowered their target price on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.